Use of CD97 Alpha Subunit Antibodies for Treatment of Angiogenesis, Atherosclerosis, and Inflammation
Posted Jun 12 2012 8:00pm
Description of Invention: CD97 is a T-cell glycoprotein that is upregulated in activated T-cells and is involved in the onset and maintenance of inflammation and angiogenesis. It is a seven-span transmembrane heterodimer consisting of one variant alpha subunit, which is soluble, and one invariant beta subunit, which is membrane-bound. Upon activation of T-cells, expression of the alpha subunit is dramatically upregulated and it is shed into the extracellular medium. The inventors have demonstrated in in vitro and in vivo studies that CD97 plays an important role in angiogenesis, inflammation, and atherosclerosis.
This technology describes isolated soluble CD97 alpha subunit proteins, selected from three alternatively spliced isoforms, as well as antibodies that bind to these subunits. The technology also describes methods of inhibiting angiogenesis, CD97-associated chronic inflammation, and atherosclerosis in mammals.
Applications: This technology may be useful for the treatment of angiogenesis-related diseases, as well as inflammation and atherosclerosis. It can also be utilized in studies of inflammation and angiogenesis.
Advantages: CD97 represents a novel target for treatment of angiogenesis- and inflammation-mediated diseases.
For Licensing Information Please Contact: Tara Kirby Ph.D. NIH Office of Technology Transfer 6011 Executive Blvd. Suite 325, Rockville, MD 20852 United States Email: firstname.lastname@example.org Phone: 301-435-4426 Fax: 301-402-0220